Menu
← Oncology Approval Tracker
FDA DECISION ·
Tevimbra
tislelizumab-jsgr · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds 150 mg every two weeks or 300 mg every four weeks as IV monotherapy for adults with unresectable or metastatic ESCC previously treated with systemic chemotherapy without a PD-1 or PD-L1 inhibitor.
LAMPGEN ANALYSIS
Why it matters
The additional intervals offer scheduling alternatives for the existing post-chemotherapy monotherapy use.
What research teams should watch
Record prior checkpoint exposure and select the regimen interval before scheduling infusion and assessment visits.
PRIMARY RECORDS